Autologous Cytokine-Induced Killer Cells Improves Overall Survival of Metastatic Colorectal Cancer Patients: Results From a Phase II Clinical Trial

Clinical Colorectal Cancer

Volumn 15, Issue 3, 2016, Pages 228-235

  Zhao, Hua ^a   Wang, Yang ^a   Yu, Jinpu ^a   Wei, Feng ^a   Cao, Shui ^a,b   Zhang, Xinwei ^a,b   Dong, Nan ^a   Li, Hui ^a   Ren, Xiubao ^a,b  

^a KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cytokine induced killer cell; Immunotherapy; Metastatic colorectal cancer; Overall survival; Progression free survival

Indexed keywords

CHINESE DRUG; FLUOROURACIL; FOLINIC ACID; IMMUNOMODULATING AGENT; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS CYTOKINE INDUCED KILLER CELL TRANSPLANTATION; AUTOTRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL TRANSPLANTATION; CHEMOTHERAPY INDUCED ANEMIA; CHINESE MEDICINE; CLINICAL EVALUATION; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; ADENOCARCINOMA; ADVERSE EFFECTS; AREA UNDER THE CURVE; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; IMMUNOTHERAPY; KAPLAN MEIER METHOD; PHASE 2 CLINICAL TRIAL; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; TRANSPLANTATION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; ROC CURVE;

EID: 84977107171     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2016.02.005     Document Type: Article

References (32)

1. 1 Jemal, A., Bray, F., Center, M.M., et al. Global cancer statistics. CA Cancer J Clin 61 (2011), 69–90.
2. 2 Van Cutsem, E., Nordlinger, B., Adam, R., et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42 (2006), 2212–2221.
3. 3 Fuchs, C.S., Marshall, J., Mitchell, E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25 (2007), 4779–4786.
4. 4 Tournigand, C., Andre, T., Achille, E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004), 229–237.
5. 5 Goldberg, R.M., Sargent, D.J., Morton, R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004), 23–30.
6. 6 Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004), 2335–2342.
7. 7 Jemal, A., Clegg, L.X., Ward, E., et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101 (2004), 3–27.
8. 8 Thirion, P., Michiels, S., Pignon, J.P., et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22 (2004), 3766–3775.
9. 9 Dougan, M., Dranoff, G., Immune therapy for cancer. Annu Rev Immunol 27 (2009), 83–117.
10. 10 Hontscha, C., Borck, Y., Zhou, H., et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137 (2011), 305–310.
11. 11 Stroncek, D., Berlyne, D., Fox, B., et al. Developments in clinical cell therapy. Cytotherapy 12 (2010), 425–428.
12. 12 Rosenberg, S., Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst 75 (1985), 595–603.
13. 13 Yun, Y.S., Hargrove, M.E., Ting, C.C., et al. In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res 49 (1989), 4770–4774.
14. 14 Schmidt-Wolf, I.G., Negrin, R.S., Kiem, H.P., et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174 (1991), 139–149.
15. 15 Ren, X., Yu, J., Liu, H., et al. Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biother Radiopharm 21 (2006), 22–33.
16. 16 Li, R., Wang, C., Liu, L., et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother 61 (2012), 2125–2133.
17. 17 Liu, L., Zhang, W., Qi, X., et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 18 (2012), 1751–1759.
18. 18 Schmidt-Wolf, I.G., Finke, S., Trojaneck, B., et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81 (1999), 1009–1016.
19. 19 Colucci, G., Gebbia, V., Paoletti, G., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23 (2005), 4866–4875.
20. 20 Tsuchida, Y., Therasse, P., Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 37 (2001), 1–3.
21. 21 Levi, F., Misset, J.L., Brienza, S., et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69 (1992), 893–900.
22. 22 Li, H., Wang, C., Yu, J., et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non–small-cell lung cancer in patients after surgery. Cytotherapy 11 (2009), 1076–1083.
23. 23 Bokemeyer, C., Bondarenko, I., Makhson, A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27 (2009), 663–671.
24. 24 Douillard, J.Y., Siena, S., Cassidy, J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28 (2010), 4697–4705.
25. 25 Kohne, C.H., Hofheinz, R., Mineur, L., et al. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 138 (2012), 65–72.
26. 26 Lee, E.K., Revil, C., Ngoh, C.A., et al. Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea. Clin Ther 34 (2012), 1408–1419.
27. 27 Madajewicz, S., Waterhouse, D.M., Ritch, P.S., et al. Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. Invest New Drugs 30 (2012), 772–778.
28. 28 Rossi, L., Veltri, E., Zullo, A., et al. Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice. Future Oncol 8 (2012), 1193–1197.
29. 29 Sobrero, A., Ackland, S., Clarke, S., et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77 (2009), 113–119.
30. 30 Tebbutt, N.C., Wilson, K., Gebski, V.J., et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28 (2010), 3191–3198.
31. 31 Van Cutsem, E., Kohne, C.H., Lang, I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29 (2011), 2011–2019.
32. 32 Correale, P., Cusi, M.G., Tsang, K.Y., et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 23 (2005), 8950–8958.